Parallax Volatility Advisers’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-493,200
| Closed | -$16.7M | – | 1782 |
|
|
2024
Q4 | $16.7M | Sell |
493,200
-100
| -0% | -$3.6K | 0.03% | 399 |
|
|
2024
Q3 | $20.2M | Buy |
493,300
+311,100
| +171% | +$12.7M | 0.04% | 335 |
|
|
2024
Q2 | $7.01M | Buy |
182,200
+11,200
| +7% | +$471K | 0.02% | 598 |
|
|
2024
Q1 | $7.33M | Buy |
171,000
+89,600
| +110% | +$3.7M | 0.02% | 605 |
|
|
2023
Q4 | $3.02M | Buy |
81,400
+79,900
| +5,327% | +$2.87M | 0.01% | 1023 |
|
|
2023
Q3 | $54.4K | Buy |
1,500
+1,100
| +275% | +$39K | ﹤0.01% | 2007 |
|
|
2023
Q2 | $14.3K | Sell |
400
-157,900
| -100% | -$5.66M | ﹤0.01% | 2161 |
|
|
2023
Q1 | $5.63M | Buy |
158,300
+100,400
| +173% | +$3.51M | 0.01% | 803 |
|
|
2022
Q4 | $2.03M | Sell |
57,900
-266,200
| -82% | -$8.87M | ﹤0.01% | 1386 |
|
|
2022
Q3 | $9.54M | Buy |
324,100
+183,300
| +130% | +$6.95M | 0.01% | 783 |
|
|
2022
Q2 | $7.66M | Buy |
140,800
+113,520
| +416% | +$6.27M | 0.01% | 830 |
|
|
2022
Q1 | $1.49M | Sell |
27,280
-65,520
| -71% | -$3.56M | ﹤0.01% | 1488 |
|
|
2021
Q4 | $5.12M | Buy |
92,800
+14,000
| +18% | +$728K | 0.01% | 780 |
|
|
2021
Q3 | $3.76M | Buy |
+78,800
| New | +$3.96M | ﹤0.01% | 919 |
|
|
2021
Q1 | – | Sell |
-11,040
| Closed | -$508K | – | 1461 |
|
|
2020
Q4 | $508K | Sell |
11,040
-34,720
| -76% | -$1.59M | ﹤0.01% | 1653 |
|
|
2020
Q3 | $2.15M | Buy |
45,760
+32,400
| +243% | +$1.62M | ﹤0.01% | 1672 |
|
|
2020
Q2 | $676K | Buy |
+13,360
| New | +$685K | ﹤0.01% | 1885 |
|
|
2020
Q1 | – | Sell |
-16,160
| Closed | -$949K | – | 2541 |
|
|
2019
Q4 | $949K | Buy |
+16,160
| New | +$899K | ﹤0.01% | 1541 |
|
|
2019
Q2 | – | Sell |
-40,000
| Closed | -$2.09M | – | 3016 |
|
|
2019
Q1 | $2.09M | Buy |
40,000
+33,840
| +549% | +$1.69M | ﹤0.01% | 986 |
|
|
2018
Q4 | $294K | Sell |
6,160
-30,640
| -83% | -$1.51M | ﹤0.01% | 1648 |
|
|
2018
Q3 | $1.85M | Sell |
36,800
-181,280
| -83% | -$9.21M | ﹤0.01% | 1050 |
|
|
2018
Q2 | $11M | Buy |
218,080
+201,840
| +1,243% | +$10.2M | 0.02% | 404 |
|
|
2018
Q1 | $793K | Buy |
+16,240
| New | +$756K | ﹤0.01% | 1013 |
|
|
2017
Q4 | – | Sell |
-26,320
| Closed | -$1.34M | – | 4325 |
|
|
2017
Q3 | $1.34M | Buy |
+26,320
| New | +$1.34M | ﹤0.01% | 972 |
|
|
2017
Q2 | – | Sell |
-73,920
| Closed | -$3.9M | – | 2918 |
|
|
2017
Q1 | $3.9M | Buy |
73,920
+21,920
| +42% | +$1.11M | 0.01% | 649 |
|
|
2016
Q4 | $2.5M | Sell |
52,000
-15,200
| -23% | -$751K | ﹤0.01% | 872 |
|
|
2016
Q3 | $3.62M | Buy |
+67,200
| New | +$3.68M | 0.01% | 805 |
|
|
2016
Q1 | – | Sell |
-116,800
| Closed | -$5.89M | – | 2964 |
|
|
2015
Q4 | $5.89M | Sell |
116,800
-110,480
| -49% | -$5.63M | 0.01% | 635 |
|
|
2015
Q3 | $10.9M | Sell |
227,280
-15,200
| -6% | -$791K | 0.02% | 411 |
|
|
2015
Q2 | $12.6M | Buy |
242,480
+202,480
| +506% | +$11.4M | 0.03% | 418 |
|
|
2015
Q1 | $2.31M | Buy |
40,000
+31,920
| +395% | +$1.83M | 0.01% | 973 |
|
|
2014
Q4 | $432K | Buy |
+8,080
| New | +$452K | ﹤0.01% | 2172 |
|
|
2014
Q1 | – | Sell |
-83,120
| Closed | -$5.55M | – | 3481 |
|
|
2013
Q4 | $5.55M | Hold |
83,120
| – | – | 0.03% | 410 |
|
|
2013
Q3 | $5.21M | Hold |
83,120
| – | – | 0.03% | 360 |
|
|
2013
Q2 | $5.19M | Buy |
+83,120
| New | +$5.28M | 0.02% | 398 |
|
Other funds holding GSK
JEST
